logo

For the Inventor, By the Inventor

Princeton, NJ, United States of America

Bristol-myers Squibb Compnay


USPTO Granted Patents = 3,684



Trademarks = 344

Forward Citations = 45,844

Loading Chart...
Loading Chart...

3,364 inventors (with patents filed for the assignee):

goldMedal Nicholas A Meanwell (120 out of 141 patents)

silverMedal John E Macor (111 out of 118 patents)

bronzeMedal John F Kadow (106 out of 136 patents)

4.  Paul Michael Scola (85 out of 87 patents)

5.  William R Ewing (70 out of 85 patents)

6.  Tao Wang (66 out of 78 patents)

7.  Jeffrey A Robl (66 out of 81 patents)

8.  James R Corte (63 out of 65 patents)

9.  Alaric J Dyckman (62 out of 63 patents)

10.  T G Murali Dhar (62 out of 64 patents)

11.  Piyasena Hewawasam (58 out of 61 patents)

12.  Robert Michael Borzilleri (57 out of 60 patents)

13.  Saleem Ahmad (56 out of 58 patents)

14.  Donald J P Pinto (56 out of 78 patents)

15.  R Michael Lawrence (55 out of 61 patents)


Core Competencies:
TLR9 Inhibitors
Therapeutic Proteins
IL-12 Modulators
Anti-PD-1 Antibodies
Heterocyclic Inhibitors
LPA Antagonists
Immunomodulators
Cancer Treatment
Monoclonal Antibodies
Protein Purification
AAV Therapy
IRAK4 Inhibitors

3,684 patents:

1. 12492217 - Reagents and their use for modular enantiodivergent synthesis of C—P bonds (2025-12-09),
2. 12492202 - Macrocyclic PAD4 inhibitors useful as immunosuppressant (2025-12-09),
3. 12492188 - 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis (2025-12-09),
4. 12486525 - Methods for increasing productivity of therapeutic proteins (2025-12-02),
5. 12486267 - Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis (2025-12-02),
6. 12485123 - 1-pyrazolo[4,3-]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists (2025-12-02),
7. 12479917 - Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody (2025-11-25),
8. 12479831 - Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators (2025-11-25),
9. 12474298 - Isoelectric focusing sample matrix (2025-11-18),
10. 12473304 - Heterocyclic PAD4 inhibitors (2025-11-18),
11. 12473290 - Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses (2025-11-18),
12. 12466804 - Cyclobutyl carboxylic acids as LPA antagonists (2025-11-11),
13. 12460173 - Control of cell growth through a temperature feedback loop (2025-11-04),
14. 12459904 - Process for preparing carbamoyloxymethyl triazole cyclohexyl acid compounds (2025-11-04),
15. 12454531 - Substituted piperazine derivatives useful as T cell activators (2025-10-28),
Bristol-Myers Squibb is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines to help patients prevail over serious diseases. With a diverse portfolio of products and a strong pipeline of potential new therapies, Bristol-Myers Squibb is at the forefront of advancing science to improve patient outcomes.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
3,684 Patents

#1 in Princeton, NJ

#7 in New Jersey

#114 in US

#240 in the World

...
Princeton, NJ, United States of America

Bristol-myers Squibb Compnay

Forward Citations = 45,844

3,364 inventors:

goldMedal Nicholas A Meanwell (120 out of 141 patents)

silverMedal John E Macor (111 out of 118 patents)

bronzeMedal John F Kadow (106 out of 136 patents)

4.  Paul Michael Scola (85 out of 87 patents)

5.  William R Ewing (70 out of 85 patents)

Please report any incorrect information to support@idiyas.com
Loading…